S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Pfenex Stock Price, News & Analysis (NYSEAMERICAN:PFNX)

$9.42
+0.22 (+2.39 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$9.13
Now: $9.42
$9.51
50-Day Range N/A
52-Week Range
$3.13
Now: $9.42
$10.20
Volume186,600 shs
Average Volume208,053 shs
Market Capitalization$297.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$297.65 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.


Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.07. The biotechnology company earned $2.81 million during the quarter, compared to analysts' expectations of $5.65 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 brokers have issued 1 year price targets for Pfenex's stock. Their forecasts range from $17.00 to $17.00. On average, they expect Pfenex's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

News stories about PFNX stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfenex earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Pfenex.

Are investors shorting Pfenex?

Pfenex saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 529,100 shares, an increase of 7.1% from the August 30th total of 493,800 shares. Based on an average daily trading volume, of 298,800 shares, the short-interest ratio is currently 1.8 days. Currently, 1.7% of the company's stock are short sold. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by many different of institutional and retail investors. Top institutional investors include Strs Ohio (0.21%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Patrick K Lucy, Phillip M Schneider and Robin Campbell. View Institutional Ownership Trends for Pfenex.

Which major investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $9.42.

How big of a company is Pfenex?

Pfenex has a market capitalization of $297.65 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  355
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel